13 August 2014Americas

Biotech industry reacts to USPTO’s Myriad/Mayo guidelines

A group of 12 international biotechnology associations has written to the US Patent and Trademark Office (USPTO), raising concerns about the office’s guidelines on determining the patent eligibility of natural products in the aftermath of the Myriad and Mayo cases.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Why the US is poised for a patent litigation surge in 2026

12 January 2026 After “seismic” changes imposed by the USPTO last year, litigating patents will become significantly more difficult and costly to defend, and both plaintiffs and defendants must urgently retool their strategies, advise lawyers from BCLP.

Americas

From migraine drugs to COVID vaccine spats, US lawsuits pile up

9 January 2026 A busy week in US courts saw major pharma companies and biotech firms move to protect key therapies and research tools, with new lawsuits over migraine and cancer drug generics, and alleged misuse of COVID-19 vaccine tech.

Americas

Insulin pump rivals face off in major trade secrets dispute hearing

8 January 2026 Important questions about when companies must act on suspicions of theft and whether damages can stack with injunctions were raised in a dispute that has already sent ripples across med tech.